NEW YORK, Feb. 15, 2019 (GLOBE NEWSWIRE) -- In
new independent research reports released early this morning,
Market Source Research released its latest key findings for all
current investors, traders, and shareholders of Tenaris S.A.
(TS), Rapid7, Inc. (RPD), Halozyme Therapeutics, Inc. (HALO), Cara Therapeutics, Inc. (CARA), EnPro Industries (NPO), and K12 Inc (LRN),
including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst
research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
TS DOWNLOAD: http://MarketSourceResearch.com/register/?so=TS
RPD DOWNLOAD: http://MarketSourceResearch.com/register/?so=RPD
HALO DOWNLOAD: http://MarketSourceResearch.com/register/?so=HALO
CARA DOWNLOAD: http://MarketSourceResearch.com/register/?so=CARA
NPO DOWNLOAD: http://MarketSourceResearch.com/register/?so=NPO
LRN DOWNLOAD: http://MarketSourceResearch.com/register/?so=LRN
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine Tenaris S.A. (TS), Rapid7, Inc. (RPD), Halozyme Therapeutics, Inc. (HALO), Cara Therapeutics, Inc. (CARA), EnPro Industries (NPO), and K12 Inc (LRN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
TENARIS S.A. (TS) REPORT OVERVIEW
Tenaris S.A's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Tenaris S.A reported revenue of $1,898.89MM vs $1,302.92MM (up 45.74%) and analysts estimated basic earnings per share $0.42 vs $0.18 (up 133.33%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Tenaris S.A reported revenue of $5,288.50MM vs $4,293.59MM (up 23.17%) and analysts estimated basic earnings per share $0.92 vs $0.09 (up 922.22%). Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.27. The estimated EPS forecast for the next fiscal year is $1.72 and is expected to report on February 20th, 2019.
To read the full Tenaris S.A. (TS) report, download it here: http://MarketSourceResearch.com/register/?so=TS
-----------------------------------------
RAPID7, INC. (RPD) REPORT OVERVIEW
Rapid7's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Rapid7 reported revenue of $62.37MM vs $50.52MM (up 23.44%) and analysts estimated basic earnings per share -$0.25 vs -$0.24. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Rapid7 reported revenue of $200.94MM vs $157.44MM (up 27.63%) and analysts estimated basic earnings per share -$1.06 vs -$1.19. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.33. The estimated EPS forecast for the next fiscal year is -$0.27 and is expected to report on February 6th, 2020.
To read the full Rapid7, Inc. (RPD) report, download it here: http://MarketSourceResearch.com/register/?so=RPD
-----------------------------------------
HALOZYME THERAPEUTICS, INC. (HALO) REPORT OVERVIEW
Halozyme Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Halozyme Therapeutics reported revenue of $25.56MM vs $63.73MM (down 59.90%) and analysts estimated basic earnings per share -$0.19 vs $0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Halozyme Therapeutics reported revenue of $316.61MM vs $146.69MM (up 115.84%) and analysts estimated basic earnings per share $0.46 vs -$0.81. Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is -$0.60 and is expected to report on February 21st, 2019.
To read the full Halozyme Therapeutics, Inc. (HALO) report, download it here: http://MarketSourceResearch.com/register/?so=HALO
-----------------------------------------
CARA THERAPEUTICS, INC. (CARA) REPORT OVERVIEW
Cara Therapeutics' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cara Therapeutics reported revenue of $0.91MM vs $0.09MM (up 959.30%) and analysts estimated basic earnings per share -$1.86 vs -$2.10. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.43. The estimated EPS forecast for the next fiscal year is -$2.26 and is expected to report on March 21st, 2019.
To read the full Cara Therapeutics, Inc. (CARA) report, download it here: http://MarketSourceResearch.com/register/?so=CARA
-----------------------------------------
ENPRO INDUSTRIES (NPO) REPORT OVERVIEW
EnPro Industries' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, EnPro Industries reported revenue of $388.20MM vs $343.70MM (up 12.95%) and analysts estimated basic earnings per share $1.17 vs $22.98 (down 94.91%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, EnPro Industries reported revenue of $1,309.60MM vs $1,187.70MM (up 10.26%) and analysts estimated basic earnings per share $25.28 vs -$1.86. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is $5.28 and is expected to report on February 12th, 2020.
To read the full EnPro Industries (NPO) report, download it here: http://MarketSourceResearch.com/register/?so=NPO
-----------------------------------------
K12 INC (LRN) REPORT OVERVIEW
K12's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, K12 reported revenue of $254.87MM vs $217.21MM (up 17.34%) and analysts estimated basic earnings per share $0.61 vs $0.34 (up 79.41%). For the twelve months ended June 30th, 2018 vs June 30th, 2017, K12 reported revenue of $917.73MM vs $888.52MM (up 3.29%) and analysts estimated basic earnings per share $0.70 vs $0.01 (up 6,900.00%). Analysts expect earnings to be released on April 23rd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.32. The estimated EPS forecast for the next fiscal year is $0.88 and is expected to report on August 6th, 2019.
To read the full K12 Inc (LRN) report, download it here: http://MarketSourceResearch.com/register/?so=LRN
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected].
LEGAL NOTICES